EX 99.1 PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2024 RESULTS Solid ARR and Cash Flow in Fourth Fiscal Quarter and Full Fiscal Year BOSTON, MA, November 6, 2024 - PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2024. "In fiscal year 2024, we again delivered solid ARR and cash flow, with year-over-year ARR growth in the low double-digits and cash flow growth above 20%. We have a differentiated strategy that leverages ou ...

文章核心观点 - PTC公司预计第四季度收入将在5.98亿美元至6.48亿美元之间,非GAAP每股收益预计在1.30美元至1.66美元之间 [1][2] - 公司的CAD和PLM解决方案业务持续成为主要收入驱动因素,有望支撑本季度表现 [3] - 公司的SLM和ALM解决方案的采用增加也可能带来额外的推动力 [4] - 公司在物联网、增强现实和人工智能等新兴技术的投资与行业趋势相符 [4] - 订阅模式转型和提高运营纪律有助于推动现金流 [5] 财务数据总结 - 第四季度预计年度经常性收入(ARR)在22亿美元至22.2亿美元之间 [5] - 第四季度预计经营活动现金流为8800万美元,自由现金流为8300万美元 [5] - 2024财年ARR预计增长11-12%,达到22亿-22.2亿美元 [5] - 2024财年收入预计增长8-11%,达到22.7亿-23.2亿美元 [5] 行业趋势和挑战 - 不利的汇率变动和疲软的需求环境可能成为阻碍 [6] - 为应对CAD和PLM领域激烈竞争而增加的研发成本可能会影响利润表现 [6]

Wall Street analysts forecast that PTC Inc. (PTC) will report quarterly earnings of $1.43 per share in its upcoming release, pointing to a year-over-year increase of 19.2%. It is anticipated that revenues will amount to $620.49 million, exhibiting an increase of 13.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed ...

Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Inc. (PTC) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than ex ...

MALVERN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new series of inrush current limiting positive temperature coefficient (PTC) thermistors. Designed to increase performance in active charge and discharge circuits for automotive and industrial applications, Vishay BCcomponents PTCEL High Energy series devices combine maximum energy handling to 340 J — five times higher than competing devices at high ambient temperatures — with a wide range of resistan ...

WARREN, N.J., Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). "The NDA acceptance for review is a significant milestone that brings us one step closer to providing this important treatment to boys and young men living with nonsense mutation Duchenne musc ...

WARREN, N.J., Oct. 24, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, Nov. 7, at 4:30 p.m. EST.To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of ...

文章核心观点 - 公司宣布FDA已经为公司提交的治疗儿童和成人苯丙酮尿症(PKU)的新药申请(NDA)设定了2025年7月29日的目标审查日期 [1] - 公司宣布APHENITY III期临床试验结果已在权威医学期刊《柳叶刀》上发表 [1] - 公司表示APHENITY III期临床试验数据和正在进行的开放标签延长研究结果显示,该药物具有持久疗效,可以让患者放宽饮食限制并仍能控制血液中苯丙氨酸水平 [2] 药物概况 - 该药物(sepiapterin)是一种口服合成sepiapterin制剂,通过双重机制作用提高苯丙氨酸羟化酶(PAH)酶活性,从而降低血液中苯丙氨酸水平,有潜力治疗各种类型的PKU患者 [3] 疾病概况 - 苯丙酮尿症(PKU)是一种罕见的遗传代谢性疾病,会影响大脑,是由帮助分解苯丙氨酸的酶缺陷引起的 - 如果不及时治疗或管理不善,体内苯丙氨酸会积累到危险水平,导致严重不可逆的并发症,如永久性智力障碍、癫痫、发育迟缓、记忆力下降、行为和情绪问题 - 全球估计有58,000人患有PKU [4] 公司概况 - 公司是一家专注于罕见疾病领域的全球生物制药公司,致力于发现、开发和商业化具有临床差异化的药物,为患有罕见疾病的儿童和成人带来益处 [5] - 公司的创新能力、全球商业化能力是支撑其丰富多样的转化性药物管线的基础 [5] - 公司的使命是为缺乏治疗选择的患者提供最佳治疗 [5]

- Statistically significant results on primary endpoint of long-term study analyses - - Following FDA pre-NDA feedback, submission on track for December 2024 - WARREN, N.J., Oct. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified endpoint for two different FA long-term extension studies was met, with highly statistically significant evidence of durable treatment benefit on disease progress ...

WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria (PKU). A Prescription Drug User Fee Act (PDUFA) target action date is expected to be provided in the Day 74 Letter. "The FDA filing acceptance for sepiapterin is a critical milestone toward bringing this potential important therapy to children and adults livi ...